Clinical Scorecard: Outcomes of Surgical Intervention Following Preventive Mastectomy in BRCA1 and BRCA2 Mutation Carriers
At a Glance
Category
Detail
Condition
Breast cancer risk in women with germline pathogenic variants in BRCA1/2 genes
Key Mechanisms
High lifetime risk of breast and ovarian cancer due to BRCA1/2 mutations; risk reduction via preventive mastectomy and salpingo-oophorectomy
Target Population
Women with confirmed germline pathogenic variants in BRCA1 or BRCA2
Care Setting
Genetic counseling and surgical oncology in specialized centers with nationwide registry follow-up
Key Highlights
Bilateral risk-reducing mastectomy (RRM) decreases breast cancer incidence by 90% or more in BRCA1/2 mutation carriers.
Skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) allow immediate breast reconstruction with comparable oncologic safety to simple mastectomy.
Long-term oncologic safety data for SSM and NSM are limited but current evidence shows low incidence (~1.9%) of primary breast cancer after bilateral RRM over 3 to 14 years.
Guideline-Based Recommendations
Diagnosis
Genetic testing for BRCA1/2 mutations in women with suspected hereditary breast and ovarian cancer.
Annual breast imaging surveillance for women with confirmed BRCA1/2 pathogenic variants.
Management
Offer risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk.
Inform women about the option of risk-reducing mastectomy (RRM) to significantly lower breast cancer risk.
Perform RRM using skin-sparing or nipple-sparing techniques to facilitate immediate breast reconstruction.
Monitoring & Follow-up
Follow-up from date of RRM or genetic testing until breast cancer diagnosis, death, emigration, or study end.
Monitor for occult breast cancer diagnosed within 90 days post-RRM.
Track postoperative complications within 30 days after surgery.
Risks
Potential residual breast tissue in skin flaps or nipple-areolar complex may theoretically increase oncologic risk, though studies show comparable outcomes.
Major surgical postoperative complications include bleeding, wound, infectious, or unspecified complications requiring intervention or readmission.
Patient & Prescribing Data
Swedish women aged 18 years or older with confirmed BRCA1/2 germline pathogenic variants without prior breast cancer.
Women undergoing RRM contribute person-years to non-RRM group until surgery; occult breast cancer cases included in non-RRM group; follow-up data linked to national cancer, patient, and death registries.
Clinical Best Practices
Centralize genetic testing and counseling to specialized laboratories and clinical genetics departments.
Use standardized diagnostic and surgical coding systems for accurate data collection and outcome analysis.
Define occult breast cancer as diagnosis within 90 days of RRM to differentiate from primary breast cancer after RRM.
Employ skin-sparing or nipple-sparing mastectomy techniques to balance oncologic safety with aesthetic outcomes and facilitate immediate reconstruction.
Monitor and manage major surgical postoperative complications within 30 days to optimize patient safety.
by Rebecca Wiberg, Signe Hägglund, Barbro Numan Hellquist, Anna Rosén, Annika Idahl, Maria Mani, Svetlana Bajalica-Lagercrantz, Hans Ehrencrona, Per Karlsson, Niklas Loman, Malin Sund, Swedish BRCA Study Group, Åke Borg, Anna Öfverholm, Anna von Wachenfeldt, Christina Edwinsdotter Ardnor, Ekaterina Kuchinskaya, Johanna Rantala, Ylva Karlsson
